Last week, a narrative landed on my desk that should have been dead on arrival. BeInCrypto—a publication ostensibly covering blockchain and digital assets—published an article using Moderna’s 177% clinical-trial-fueled spike as a template to recommend three traditional equities: Intel, Target, and Macy’s. The logic was elegant in its simplicity: find stocks with high short interest, analyst skepticism, and low put/call ratios, then wait for a catalyst to trigger a short squeeze. Moderna worked. Why wouldn’t these?
Because code is law, but incentives are the reality. And in both crypto and traditional markets, the incentives behind a single explosive event rarely replicate across different assets, sectors, or timeframes. I’ve spent the better part of a decade mapping liquidity flows across crypto and traditional finance, and I’ve seen this pattern fail repeatedly. The Moderna template is a classic case of survivorship bias dressed up as a trading system. Let me deconstruct it systematically.
Context: The Original Blueprint
The original article—published on BeInCrypto, which I’ll note is a crypto news site, not a traditional equity research desk—identified three stocks: Intel (INTC), Target (TGT), and Macy’s (M). Each was selected based on a checklist derived from Moderna’s 2020 surge: - High short interest relative to float. - Analyst price targets below current price (indicating skepticism). - Elevated put/call ratios (bearish options positioning). - Technical patterns suggesting a breakout from a consolidation or downtrend.
Moderna’s move was driven by a binary event: positive Phase 3 trial results for its COVID-19 vaccine. The short squeeze was a byproduct of extreme uncertainty turning into extreme certainty. The market had mispriced the probability of success, and when the data hit, the reversal was violent. The article then extrapolated that same structure to Intel’s 14Å design kit announcement, Target’s retail turnaround narrative, and Macy’s upcoming earnings. It even provided precise entry and exit levels: Intel above $106.91, Target above $161.96, Macy’s above $29.01.
On the surface, this sounds like disciplined risk management. But the deeper problem is that the catalyst mechanism is fundamentally different. Moderna’s catalyst was a binary scientific outcome. Intel’s 14Å is a process node update—important, but incremental, not binary. Target’s recovery depends on consumer spending trends, which are macro-driven. Macy’s earnings are a quarterly report, not a binary event. The template assumes that all three will experience a similar asymmetry of information and sentiment reversal, but the underlying market microstructure is nothing alike.
Core: A Technical Deconstruction of Each Pick
Let me walk through each stock using the same data the original article cited, but with a focus on the hidden assumptions.
Intel (INTC):
At the time of writing, Intel had a short interest of around 2.5% of float—hardly extreme. The put/call ratio was elevated but not off the charts. The catalyst was the 14Å design kit release, which is a technical milestone for Intel’s foundry business. However, unlike Moderna’s clinical results, this is a gradual process. The market already knows Intel is investing in advanced nodes. A design kit release is expected, not a surprise. The real question is whether Intel can win back customers like AMD or Nvidia. That’s a multi-year thesis, not a squeeze trigger.
From my own liquidity mapping framework, I tracked on-chain signals for semiconductor stocks in 2023–2024. The correlation between foundry news and stock price is weak. In fact, Intel’s stock has been range-bound between $30 and $50 for two years. The breakout level of $106.91 is 100% above the current price—a massive leap that implies a near-halving of the discount rate. Without a fundamental shift in revenue growth or margin expansion, that target is aspirational. The original article provided a stop-loss at $81.88, which is 20% below the current price. That’s a wide stop, suggesting a low probability of the upside being realized.
Target (TGT):
Target’s short interest was around 4%—moderate. The put/call ratio was bearish, and analysts were indeed skeptical after a disappointing holiday season. The original article cited a technical breakout above $161.96 as the trigger. The problem is that Target’s rise was accompanied by declining volume, which is a classic sign of weak buying pressure. In my experience auditing yield mechanics in DeFi, I’ve seen the same pattern: a price move without volume confirmation is like a yield without locked liquidity—it’s unsustainable. The catalyst for Target is the consumer spending outlook, which is tied to interest rates. If the Fed cuts rates, Target benefits. But if rates stay high, the retailer faces margin compression. The original article ignored this macro dependency.
Macy’s (M):
Macy’s had the highest short interest of the three, around 9% of float. The put/call ratio was skewed bearish. The technical setup showed a potential breakout from a descending channel, with a key level at $29.01. The catalyst was the September 10 earnings report. This is the closest to a binary event, but Macy’s is a declining department store chain. Its revenue has been shrinking for years. A short squeeze would require a massive earnings beat, which is possible but not probable. The original article used the same template as Moderna, but Moderna’s beat was a 95% efficacy result—a fundamental shift in the company’s value. Macy’s could beat by 10% and still be facing secular decline. The template fails to account for the difference between a temporary catalyst and a structural change.
My analysis of the three stocks shows a common flaw: the original article treats each as a symmetrical bet on a short squeeze, but the asymmetry of outcomes is vastly different. Moderna had a binary outcome with a high payoff if correct. These three have a range of outcomes, with the most likely being a modest move or a failure. The article provides no probability weighting, no backtest, and no consideration of correlation between the three picks. If Intel misses, will Target and Macy’s still work? The original article assumes independence, but economic cycles tie them together.
Contrarian: The Decoupling Thesis
Here’s where my contrarian view diverges from the original article. The real risk is not that these stocks will fail—it’s that the template itself is a cognitive trap. In crypto, we see the same pattern every cycle: "This coin will do a Solana-like run," or "This DeFi protocol will follow Uniswap’s path." The Moderna template is a form of narrative trading, where a single success story is used to justify a set of picks, ignoring the unique market microstructure of each asset.
Let me give you a concrete example from my own experience. In 2021, I audited the yield mechanics of several DeFi protocols that claimed to be the "next Compound." The original Compound had a massive liquidity bootstrapping event because it was first to market with a novel lending mechanism. The imitators had the same code but different incentive structures—they lacked the network effects and the timing. Most failed. Similarly, Moderna’s success was a function of being first in a pandemic, with a novel mRNA technology. Intel, Target, and Macy’s are not first; they are incumbents facing structural headwinds. The decoupling thesis is that these stocks are not "Moderna-like" at all—they are value traps with temporary technical setups.
From a macro perspective, the original article ignores the interest rate environment. Moderna’s spike happened in a low-rate, high-liquidity environment where speculation was rampant. Today, rates are at 5.25%, and liquidity is being drained. The Federal Reserve’s balance sheet is shrinking. In that environment, short squeezes are rarer and shorter-lived. The original article’s implicit assumption that the macro environment is neutral is a blind spot. I’ve written before that "speculation is noise, liquidity is signal." The current liquidity map shows capital flowing out of equities into money markets. A squeeze requires a catalyst that overcomes that headwind.
Takeaway: Positioning for the Cycle
The original article represents a specific type of investment behavior: event-driven pattern matching. It’s not wrong per se, but it’s incomplete. The forward-looking question is not whether Intel, Target, or Macy’s will rally—it’s whether the template itself is reproducible. Based on my experience mapping liquidity flows and auditing yield structures, the answer is no. The Moderna template worked because of a once-in-a-century pandemic, a binary scientific result, and a historically accommodative monetary policy. Replicating that in 2025 with three mature, cyclical stocks is a stretch.
For crypto investors reading this, the lesson is clear: avoid linear extrapolation. When you see a headline like "This token will do a Solana-like run," ask yourself: what is the unique catalyst? Is it binary? Is the liquidity environment similar? Are the incentives aligned? If the answer is "it’s just like Moderna," run the other way.
Code is law, but incentives are the reality. The original article’s incentives are to generate clicks and engagement, not to provide a robust, repeatable strategy. The onus is on the reader to apply the same skepticism that the article claims to exploit. When the next "Moderna-like" setup appears, will you know the difference between a catalyst and a coincidence?
